Tumor markers CA 19‐9 and CA 195 are also useful as markers for cystic fibrosis

Wu, James T.; Olson, June; Kay, Walker

doi:10.1002/jcla.1860060310

Cited by 9 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with CF have shown to experience non-specific elevations in serum CA-19-9 levels, with volumes up to 500 U/mL (reference range 0-37 U/mL)[ 55 - 58 ]. Some sources have linked increased serum CA-19-9 Levels with active CF-related liver disease[ 54 ] and pulmonary exacerbation[ 57 , 59 - 61 ]. CA-19-9 has a 20% false-positive rate as a screening test and the serum level may also be elevated with other conditions, including an increased production of sputum, diabetes, chronic kidney failure, and infections.…”

Section: Rationale For Screening Of Gi and Hepatopancreatobiliary Cancersmentioning

confidence: 99%

Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis

Hoskins

Wasuwanich

Scheimann

et al. 2021

WJGO

View full text Add to dashboard Cite

Based on systematic review and meta-analysis, the risk for developing cancers in patients with cystic fibrosis (CF) is known to be significantly greater than in the general population, including site-specific cancers of the esophagus, small bowel, colon, liver, biliary tract, and pancreas. An even higher risk has been found in patients who have severe CF transmembrane conductance regulator ( CFTR ) genotypes or who have undergone organ transplantation and are immunosuppressed. The risk continues to rise as life expectancies steadily climb due to advancements in medical care and treatment for CF. The colorectal cancer risk is at such a high level that CF has now been declared a hereditary colon cancer syndrome by the Cystic Fibrosis Foundation. The CFTR gene has been strongly-associated with the development of gastrointestinal (GI) cancers and mortality in the CF population. Even CF carriers have shown an increased rate of GI cancers compared to the general population. Several limitations exist with the reported guidelines for screening of GI and hepatopancreatobiliary cancers in the CF population, which are largely universal and are still emerging. There is a need for more precise screening based on specific risk factors, including CFTR mutation, medical co-morbidities (such as gastroesophageal reflux disease, distal intestinal obstruction syndrome, and diabetes mellitus), familial risks for each cancer, gender, age, and other factors. In this review, we propose changes to the guidelines for GI screening of patients with CF. With the development of CFTR modulators, additional studies are necessary to elucidate if there is an effect on cancer risk.

show abstract

Section: Rationale For Screening Of Gi and Hepatopancreatobiliary Cancersmentioning

confidence: 99%

Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis

Hoskins

Wasuwanich

Scheimann

et al. 2021

WJGO

View full text Add to dashboard Cite

show abstract

“…We studied the CA 19-9 molecule from sputum extracts because the CA 19-9 molecule in the CF serum most likely originated from sputum and because sputum contains extremely high concentrations of CA 19-9 activity (13). Once again CA 19-9 molecules of both sizes could be found in the sputum extract.…”

Section: Sputamentioning

confidence: 99%

Chromatographic characterization of CA 19‐9 molecules from cystic fibrosis and pancreatic carcinoma

Wu¹,

Chang²

1992

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

We have compared the size, the binding to Concanavalin A (Con A), and the affinity for monoclonal antibody 1116NS-199 (Mab 19-9) among CA 19-9 molecules from sera of cystic fibrosis (CF) and pancreatic carcinoma patients and from sputum extracts. CA 19-9 molecules of two different sizes were found in all types of specimens by Sepharose 4B chromatography. While the smaller CA 19-9 molecule was predominant in CF patient sera, the larger molecule was associated with most of the sera from patients with pancreatic carcinoma. The majority of the sputum extracts contained the larger CA 19-9 molecule. All CA 19-9 molecules studied by Con A chromatography did not appear to bind to Con A, and almost 100% were found in the nonreactive fraction. The CA 19-9 molecules from sera of either CF or pancreatic carcinoma patients exhibited variable affinities for Mab 19-9, some approaching that of the standard curve but many also having lower affinities. The lowest affinity was displayed by CA 19-9 molecules from the sputum extract. It appears that development of more specific assays for CF and for carcinoma is possible if the correct CA 19-9 molecule is selected for antibody preparation and for use as standards.

show abstract

Development of radioimmunoassays on microplate: Application for CA‐GI and CA‐Br tumor markers

Erali

1993

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

By taking advantage of a newly available microplate counter for radioactivity and the organic solvent-resistant, pigmented microplates, we have successfully established radioimmunoassays (RIA) for both CA-GI and CA-BR on microplate for routine clinical use. In the process of assay development, we found that both pigmented PicoPlate, made of acrylonitrile, and polystyrene Microlite 2 can be coated with antialpha fetoprotein (AFP) and antinerve growth factor (NGF) and used for setting up immunoassays for AFP and nerve growth factors. There were no problems following a test format of either competitive binding or sandwich design. Microlites 2 is recommended over PicoPlate because Microlites 2 is made of polystyrene, which is less expensive and separable into 8-well strips or even single wells. Single-well separation allows for the use of regular gamma counters in case Topcount is unavailable. We also found that the sensitivity of these tests was not significantly affected even though Topcount counts the weaker beta emissions. Similar dose-response curves could also be generated between original Biomira tube assays and assays using PicoPlate or Microlite 2 coated with protein antigens CA-Br and CA-GI. Excellent correlations were also obtained between the microplate assays and the Biomira tube assays for CA-GI and CA-Br using groups of serum specimens from cancer patients. We recommend the development of various RIAs on the microplate: it requires less reagents and less sample handling by the technologists and it can be essentially automated.

show abstract

Tumor markers CA 19‐9 and CA 195 are also useful as markers for cystic fibrosis

Cited by 9 publications

References 28 publications

Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis

Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis

Chromatographic characterization of CA 19‐9 molecules from cystic fibrosis and pancreatic carcinoma

Development of radioimmunoassays on microplate: Application for CA‐GI and CA‐Br tumor markers

Contact Info

Product

Resources

About